Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GB-5001 (Donepezil IM Depot) in Healthy Volunteers
NCT05525780Phase 1Completed
- Sponsor
- G2GBIO
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of donepezil in Alzheimer's disease (AD) (3 arms), sponsored by G2GBIO. Primary endpoints: Adverse Events at Day 64, Vital Signs at Day 64 and 3 more. Started Aug 2022; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05525780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525780.